Mitochondrial-Targeting MET Kinase Inhibitor Kills Erlotinib-Resistant Lung Cancer Cells

[Image: see text] Lung cancer cells harboring activating EGFR mutations acquire resistance to EGFR tyrosine kinase inhibitors (TKIs) by activating several bypass mechanisms, including MET amplification and overexpression. We show that a significant proportion of activated MET protein in EGFR TKI-res...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ACS Med Chem Lett
Hlavní autoři: Yang, Tianming, Ng, Wai Har, Chen, Huan, Chomchopbun, Kamon, Huynh, The Hung, Go, Mei Lin, Kon, Oi Lian
Médium: Artigo
Jazyk:Inglês
Vydáno: American Chemical Society 2016
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4983733/
https://ncbi.nlm.nih.gov/pubmed/27563407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.6b00223
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky